Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline
Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2 Solid Tumor Clinical Trial Dosed First Patient in RTX-240 Phase 1 Relapsed/Refractory...
Day: November 9, 2020
Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered...
Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Graphic Anti-SARS-COV-2 antibody response (IgG and IgM) to trimeric spike protein and RBD of SARS-CoV-2. Patients received a 0.3, 1.0...
Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare Diseases
State-of-the-art facility to be located in Bedford, Massachusetts NOVATO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a...
Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression...
Genocea Presents Positive GEN-009 Clinical Results, Update on GEN-011 Program and New InhibigenTM Mechanism of Action Data at Virtual SITC 2020
Novel clinical and durable immune response patterns suggest addition of GEN-009 may offer additive clinical benefit in combination with PD-1-based...
Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab...
Celldex Presents Data from Oncology Portfolio at SITC 2020
-- Agonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated----Axl and CDX-527 programs highlighted-- HAMPTON, N.J., Nov. 09,...
Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
44.0% objective response rate and 10.3-month median progression-free survival observed in non-small cell lung cancer (NSCLC) cohort Phase 3 registration-enabling...
Myriad Genetics Delivers 56% Sequential Increase in Quarterly Revenue; Test Volumes Reach 90% of Pre-COVID-19 Level at End of Quarter
Highlights: Revenue of $145.2 million up 56% sequentially in quarter ended Sept. 30, 2020 GAAP operating income increased $28.7 million...
Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual Meeting
RTX-240 Demonstrates Promotion of T Cell and Natural Killer Cell Activation and Expansion In Vitro and In Vivo CAMBRIDGE, Mass.,...
Iovance Biotherapeutics Presents Clinical Data in Head and Neck Cancer at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
44.4% Overall Response Rate (ORR) and Median Duration of Response (DOR) Not Reached at 8.6 Months of Study Follow Up...
ZAGENO Doubles Engineering to Support High-Paced, Customer-Centric Operating Model Under Leadership of New VP of Engineering
Mathias Mandt Mathias Mandt, ZAGENO's vice president of engineering CAMBRIDGE, Mass. and BERLIN, Germany and WROCLAW, Poland, Nov. 09, 2020 (GLOBE...
Jounce Therapeutics to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Summit
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery...
Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”,...
Kleo Pharmaceuticals Presents Preclinical Proof-of-Concept Data on a Novel Chemical Conjugation Platform (MATE™) at the Society for Immunotherapy of Cancer’s (SITC) 35th Annual Meeting
NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific...
Acepodia to Present Late-breaking Poster Presentation Supporting the Potential of its NK Cell Therapy in Solid Tumors at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting
ACE1702 demonstrates enhanced cytotoxicity against multiple HER2-expressing cell lines and activity under immunosuppressive conditions ACE1702 maintains activity following cryopreservation oNK...
Codiak Presents Preclinical Data at SITC 2020 Demonstrating Potential of engEx™ Engineered Exosomes to Stimulate Targeted, Integrated Anti-Tumor Immunity
– exoIL-12™ demonstrates tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo –...
Aldevron Names Shawn McCormick Chief Financial Officer
FARGO, N.D.--(BUSINESS WIRE)--#Aldevron--Aldevron, a global leader in the manufacture of plasmid DNA, mRNA and proteins, today announced Shawn McCormick as...
Outset Medical Appoints Steve Williamson as Chief Commercial Officer
Former Worldwide President of Becton Dickinson Peripheral Intervention Business Unit to Oversee Rapid Commercial Expansion SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical,...